CompletedNot Applicable

Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab

10 participantsStarted 2010-03-01

Plain-language summary

To asses the use of golimumab, a fully humanized anti-TNF Alpha monoclonal antibody, in juvenile idiopathic Arthritis-associated uveitis refractory to adalimumab.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * JIA associated Uveitis * Treatment failure with adalimumab Exclusion Criteria: * Uveitis due to other causes * Adalimumab Initiation because of non ocular reasons

What they're measuring

Number of Participants Reported as Complete Responders to Golimumab

Timeframe: last follow up, up to 5 years

Trial details

NCT IDNCT04200833

SponsorMedical University of Graz

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-07-01

Results submitted2021-10-20

View on ClinicalTrials.gov More JIA Associated Uveitis trials